ImmunoCellular Therapeutics

About:

ImmunoCellular Therapeutics is focused on improving cancer treatment and diagnosis through the development of new immune-based products.

Website: http://www.imuc.com

Twitter/X: ImmunoCellular

Top Investors: Asset Management Ventures (AMV), California Institute for Regenerative Medicine

Description:

ImmunoCellular Therapeuti is a clinical-stage biotechnology company. It is engaged in developing immune-based therapies for the treatment of cancers which can elicit an immune response against several antigens. The company has developed ICT-107, which is a dendritic cell (DC) immunotherapy for the treatment of newly diagnosed glioblastoma multiforme (GBM), which is a lethal type of brain cancer. It develops Immunotherapies for treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.

Total Funding Amount:

$32.5M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Calabasas, California, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)imuc.com

Founders:

John S. Yu

Number of Employees:

1-10

Last Funding Date:

2015-09-24

IPO Status:

Public

Industries:

© 2025 bioDAO.ai